Skip to content
hcg-service-hero-1

Insights From Halloran

Halloran Consulting GroupJan 8, 2020 5:06:00 PM3 min read

Working with the Right Type of Regulatory Affairs Professional

In looking back at my 3+ decades of experience with the pharmaceutical and medical device ...
Start Reading
Halloran Consulting GroupDec 30, 2019 2:31:00 PM3 min read

ASH 2019: Themes and Trends Heading into 2020

The American Society of Hematology (ASH) Annual Meeting & Exposition is the largest ...
Start Reading
Halloran Consulting GroupDec 12, 2019 4:23:00 PM1 min read

3 Tips for Expediting Your Drug Development Program

Last week, I led an engaging discussion at BioLabs San Diego on how life science ...
Start Reading
Rashida ChallengerNov 25, 2019 4:17:00 PM5 min read

Diversity in Clinical Trials

As an industry, our primary goal is to bring safe and effective medications to the ...
Start Reading
Sheila GwizdakNov 19, 2019 2:04:00 PM2 min read

Five Tips for Implementing Quality as a Culture in Your Organization

Last week, I led an engaging discussion at BioLabs San Diego on the concept of “quality ...
Start Reading
Halloran Consulting GroupNov 18, 2019 4:16:00 PM9 min read

Declining Innovation in the Pharmaceutical Industry

Despite the increasing demand for new drugs to address unmet and underserved medical ...
Start Reading
Halloran Consulting GroupNov 15, 2019 4:24:00 PM4 min read

Operationalizing Complex Clinical Trials

This article was originally published on November 14th, 2019 in Applied Clinical Trials.
Start Reading
Halloran Consulting GroupNov 5, 2019 4:18:00 PM6 min read

A Rare Opportunity 

I attended the NORD 2019 Summit in Washington, DC a few weeks ago. It was my first chance ...
Start Reading
Halloran Consulting GroupJul 15, 2019 4:02:00 PM< 1 min read

Foundation NYC Recap

Halloran was proud to sponsor Foundation NYC, an annual event for entrepreneurs and ...
Start Reading
Halloran Consulting GroupJun 6, 2019 4:14:00 PM5 min read

Maximize Patient Engagement in Rare and Orphan Disease Clinical Trials

While it may seem obvious that clinical trials for rare and orphan disease groups are the ...
Start Reading